# Early and Late Prognosis in Patients With Guillain-Barre Syndrome

> **NCT06041451** · PHASE4 · UNKNOWN · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 450 (estimated)

## Conditions studied

- Guillain-Barre Syndrome

## Interventions

- **DRUG:** Intravenous Immunoglobulins, Human
- **DRUG:** Methylprednisolone 500 MG Injection

## Key facts

- **NCT ID:** NCT06041451
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01-02
- **Primary completion:** 2022-12-01
- **Final completion:** 2025-01-31
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041451, "Early and Late Prognosis in Patients With Guillain-Barre Syndrome". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06041451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*